|
Author: K. Sullivan, F. Wigley, C. Denton, J. van Laar, D. Furst Date Published: January-2012 Source: The Lancet
Richard Burt and colleagues (Aug 6, p 498)1 propose, on the basis of a single-centre trial of 19 patients, that autologous haemopoietic stem-cell transplantation (HSCT) might be the new standard of care for diffuse systemic sclerosis. Although the study strongly supports the use of immunosuppression in systemic sclerosis, several limitations are to be noted.
|